Autoimmune thyroid diseases in women with breast cancer and colorectal cancer.

The aim of the study was to compare the prevalence of autoimmune thyroid diseases in three groups of women (66 with breast cancer (CaB), 68 with colorectal cancer (CaC) and 49 without oncological diseases as a control group). Serum levels of thyroid-stimulating hormone (TSH), free thyroxin (fT4), antibodies to thyroglobulin (TGB-ab) and thyroperoxidase (TPO-ab) and tumor markers CEA, CA 15-3 and CA 19-9 were investigated in all subjects by using the chemiluminiscence method. In contrast to Graves' disease (no observed case), autoimmune thyroiditis was diagnosed in 24.2 % women with CaB (4.5 % euthyroid and 19.7 % with subclinical or overt hypothyroidism), compared to 16.7 % in women with CaC (2.0 % euthyroid and 14.7 % with subclinical or overt hypothyroidism) and 16.2 % controls (4.0 % euthyroid and 12.2 % with subclinical or overt hypothyroidism). Serum levels of TGB-ab were higher in the group with breast cancer as compared to those with colorectal cancer and the control group (medians: 35.80 vs. 31.75 vs. 27.70, p<0.001). Similarly, the percentage of positive TGB-ab and TPO-ab serum levels was higher in women with breast cancer as compared to those with colorectal cancer and the control group. The results of the study support the controversial theory that there is an increased prevalence of autoimmune thyroiditis in women with breast cancer.

[1]  Rajesh Singh,et al.  Functional Expression of Sodium Iodide Symporter (NIS) in Human Breast Cancer Tissue , 2004, Breast Cancer Research and Treatment.

[2]  M. van de Rijn,et al.  Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. , 2003, The Journal of clinical endocrinology and metabolism.

[3]  C. Ginter,et al.  The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. , 2003, Endocrine reviews.

[4]  J. Jiskra,et al.  IgA and IgG antigliadin, IgA anti-tissue transglutaminase and antiendomysial antibodies in patients with autoimmune thyroid diseases and their relationship to thyroidal replacement therapy. , 2003, Physiological research.

[5]  J. Stachura,et al.  Expression of the Na(+)/I(-) symporter in invasive ductal breast cancer. , 2003, Folia histochemica et cytobiologica.

[6]  C. Spitzweg,et al.  The sodium iodide symporter: its pathophysiological and therapeutic implications , 2002, Clinical endocrinology.

[7]  C. Dayan,et al.  Whose normal thyroid function is better—yours or mine? , 2002, The Lancet.

[8]  C. Markopoulos,et al.  Autoimmune thyroid disease in women with breast carcinoma. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[9]  M. Mcdermott,et al.  Subclinical hypothyroidism is mild thyroid failure and should be treated. , 2001, The Journal of clinical endocrinology and metabolism.

[10]  C. Ginter,et al.  Journey of the iodide transporter NIS: from its molecular identification to its clinical role in cancer. , 2001, Trends in biochemical sciences.

[11]  M. Ludgate,et al.  Identification of antigenic domains on the human sodium‐iodide symporter which are recognized by autoantibodies from patients with autoimmune thyroid disease , 2001, Clinical and experimental immunology.

[12]  U. Feldt-Rasmussen.  Iodine and cancer. , 2001, Thyroid : official journal of the American Thyroid Association.

[13]  N. Morgenthaler,et al.  Autoimmunity involving the human sodium/iodide symporter: fact or fiction? , 2001, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[14]  J. Wemeau,et al.  [Analysis for the diagnosis of auto-immune thyroid disease: contribution of the laboratory]. , 2001, Annales de biologie clinique.

[15]  K. Midthjell,et al.  Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The Health Study of Nord-Trondelag (HUNT). , 2000, European journal of endocrinology.

[16]  S. Jhiang,et al.  Hormonal regulation of radioiodide uptake activity and Na+/I- symporter expression in mammary glands. , 2000, The Journal of clinical endocrinology and metabolism.

[17]  E. McDermott,et al.  Tissue iodine content and serum-mediated 125I uptake-blocking activity in breast cancer. , 2000, The Journal of clinical endocrinology and metabolism.

[18]  S. Filetti,et al.  Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. , 1999, European journal of endocrinology.

[19]  Masahide Takahashi,et al.  Wakame Seaweed Suppresses the Proliferation of 7,12‐Dimethylbenz(a)‐anthracene‐induced Mammary Tumors in Rats , 1999, Japanese journal of cancer research : Gann.

[20]  J. Köhrle,et al.  Implications of the molecular characterization of the sodium-iodide symporter (NIS). , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[21]  M. Ludgate,et al.  The sodium iodide symporter gene and its regulation by cytokines found in autoimmunity. , 1998, The Journal of endocrinology.

[22]  E. McDermott,et al.  Serum thyroid peroxidase autoantibodies, thyroid volume, and outcome in breast carcinoma. , 1998, The Journal of clinical endocrinology and metabolism.

[23]  C. Spitzweg,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Analysis of Human Sodium Iodide Symporter Gene Expression in Extrathyroidal Tissues and Cloning of Its Complementary Deoxyribonucleic Acids from S , 2022 .

[24]  J. Barkmanova,et al.  [Frequent incidence of thyropathies in women with breast carcinoma]. , 1998, Vnitrni lekarstvi.

[25]  K. Mizia-Stec,et al.  [Mastopathy and simple goiter--mutual relationships]. , 1998, Przeglad lekarski.

[26]  P. Lønning,et al.  Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. , 1998, Scandinavian journal of clinical and laboratory investigation.

[27]  S. Jhiang,et al.  Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. , 1997, Endocrinology.

[28]  P. Smyth,et al.  The thyroid and breast cancer: a significant association? , 1997, Annals of medicine.

[29]  J. Horiguchi,et al.  Changes of cytokines and thyroid function in patients with recurrent breast cancer. , 1997, Anticancer research.

[30]  E. McDermott,et al.  Thyroid disorders and breast cancer. , 1998, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[31]  K. Mizia-Stec,et al.  [Fibrocystic disease of breast and pituitary-thyroid axis function]. , 1996, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego.

[32]  J. Barkmanova,et al.  [Thyroid gland function in women with breast carcinoma]. , 1996, Vnitrni lekarstvi.

[33]  J. Horiguchi,et al.  Relationship between thyroid-pituitary function and response to therapy in patients with recurrent breast cancer. , 1996, Anticancer research.

[34]  J. Geraghty,et al.  A direct relationship between thyroid enlargement and breast cancer. , 1996, The Journal of clinical endocrinology and metabolism.

[35]  T. Imai,et al.  Suppressive effect of iodine on DMBA‐induced breast tumor growth in the rat , 1996, Journal of surgical oncology.

[36]  J. French,et al.  The incidence of thyroid disorders in the community: a twenty‐year follow‐up of the Whickham Survey , 1995, Clinical endocrinology.

[37]  R. Monson,et al.  Benign thyroid diseases and the risk of death from breast cancer. , 1992, Oncology.

[38]  B. Eskin.  Iodine and mammary cancer. , 1977, Advances in experimental medicine and biology.